Related Experiment Video
Updated: Jul 17, 2026
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
New, expanded, and modified use of approved antineoplastic agents in ovarian cancer
1Department of Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center (Mail Box 121), 1515 Holcombe Boulevard, Houston, Texas 77030, USA. mmarkman@mdanderson.org
Abstract:
Over the past several years, clinical research efforts in ovarian cancer employing a number of U.S. Food and Drug Administration (FDA)-approved antineoplastic agents have permitted the development of approaches that both improve the effectiveness and decrease the toxicities of systemic therapy of ovarian cancer. These initiatives, including prospective trials and retrospective examinations of large clinical experience, have involved agents previously approved by the FDA for use in ovarian cancer (e.g., cisplatin, paclitaxel, topotecan, and liposomal doxorubicin) and the development of new strategies for drugs approved for other malignant conditions (e.g., gemcitabine, docetaxel, etoposide, irinotecan, vinorelbine, and bevacizumab). It can be anticipated that future studies involving novel approved agents will further expand the oncologist's weapons against ovarian cancer.
Insights
Clinical research in ovarian cancer has improved systemic therapy effectiveness and reduced toxicity using FDA-approved drugs. Future studies with novel agents will further enhance treatment options for ovarian cancer patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ovarian cancer treatment has advanced through clinical research.
- Systemic therapy effectiveness and toxicity have been improved.
Purpose of the Study:
- To review the development of improved systemic therapy approaches for ovarian cancer.
- To highlight the use of FDA-approved antineoplastic agents in ovarian cancer treatment.
Main Methods:
- Review of prospective clinical trials and retrospective analyses.
- Examination of U.S. Food and Drug Administration (FDA)-approved antineoplastic agents.
Main Results:
- Established FDA-approved drugs (cisplatin, paclitaxel, topotecan, liposomal doxorubicin) have been utilized.
- New strategies involve drugs approved for other cancers (gemcitabine, docetaxel, etoposide, irinotecan, vinorelbine, bevacizumab).
Conclusions:
- Clinical research has led to more effective and less toxic ovarian cancer systemic therapies.
- Ongoing studies with novel agents are expected to expand therapeutic options.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...